Heterogeneity of the tumor vasculature

Seminars in Thrombosis and Hemostasis

Volumn 36, Issue 3, 2010, Pages 321-331

  Nagy, Janice A ^a   Chang, Sung Hee ^a,b   Shih, Shou Ching ^a   Dvorak, Ann M ^a   Dvorak, Harold F ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Angiogenesis; Arterio venogenesis; Tumors; Vascular endothelial growth factor; VEGF A

Indexed keywords

ADENOVIRUS VECTOR; CATHEPSIN; CATHEPSIN B; CELL PROTEIN; CYSTEINE PROTEINASE INHIBITOR; FIBRIN; TRANSMEMBRANE 4 L SIX FAMILY 1 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; BASEMENT MEMBRANE; BLOOD VESSEL PERMEABILITY; CAPILLARY; CELL DIVISION; CELL ORGANELLE; CLASSIFICATION; DRUG TARGETING; ENDOTHELIUM CELL; GENE EXPRESSION; GLOMERULOID MICROVASCULAR PROLIFERATION; HUMAN; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE RELAXATION; TUMOR VASCULARIZATION; VASCULAR BASEMENT MEMBRANE; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASODILATATION; VENULE; VESICULO VACUOLAR ORGANELLE;

ANGIOGENESIS INHIBITORS; ANIMALS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77953257462     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0030-1253454     Document Type: Review

References (60)

1. Holash J, Maisonpierre P C., Compton D et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999 284 (5422) 1994-1998
2. Leenders W P., Küsters B, de Waal R M. Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis. Endothelium 2002 9 (2) 83-87
3. Du R, Lu K V., Petritsch C et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008 13 (3) 206-220
4. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971 285 (21) 1182-1186
5. Warren B. The vascular morphology of tumors In: Peterson H-I Tumor Blood Circulation: Angiogenesis, Vascular Morphology and Blood Flow of Experimental and Human Tumors. Boca Raton, FL CRC Press 1979 1-47
6. Stubbs M, McSheehy P M., Griffiths J R., Bashford C L. Causes and consequences of tumour acidity and implications for treatment. Mol Med Today 2000 6 (1) 15-19
7. Semenza G L. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol Med 2001 7 (8) 345-350
8. Nagy J A., Feng D, Vasile E et al. Permeability properties of tumor surrogate blood vessels induced by VEGF-A. Lab Invest 2006 86 (8) 767-780
9. Dvorak H. Tumor blood vessels In: Aird W The Endothelium: A Comprehensive Reference. Cambridge, United Kingdom Cambridge University Press 2007
10. Dvorak H F. Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma. Am J Pathol 2003 162 (6) 1747-1757
11. Dvorak H F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986 315 (26) 1650-1659
12. Chang H Y., Sneddon J B., Alizadeh A A. et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004 2 (2) E7
13. Brown L F., Berse B, Jackman R W. et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995 26 (1) 86-91
14. Guidi A J., Abu-Jawdeh G, Berse B et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 1995 87 (16) 1237-1245
15. Ellis L M., Rosen L, Gordon M S. Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignancies. Clin Adv Hematol Oncol 2006 4 (suppl) 1-12
16. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 350 (23) 2335-2342
17. Jain R K., Duda D G., Clark J W., Loeffler J S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006 3 (1) 24-40
18. Pettersson A, Nagy J A., Brown L F. et al. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest 2000 80 (1) 99-115
19. Nagy J A., Dvorak H F., Dvorak A M. VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol 2007 2 251-275
20. Sundberg C, Nagy J A., Brown L F. et al. Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery. Am J Pathol 2001 158 (3) 1145-1160
21. Nagy J A., Vasile E, Feng D et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med 2002 196 (11) 1497-1506
22. Nagy J A., Vasile E, Feng D et al. VEGF-A induces angiogenesis, arteriogenesis, lymphangiogenesis, and vascular malformations. Cold Spring Harb Symp Quant Biol 2002 67 227-237
23. Dadras S S., Detmar M. Angiogenesis and lymphangiogenesis of skin cancers. Hematol Oncol Clin North Am 2004 18 (5) 1059-1070, viii
24. He Y, Karpanen T, Alitalo K. Role of lymphangiogenic factors in tumor metastasis. Biochim Biophys Acta 2004 1654 (1) 3-12
25. Jain R K. Angiogenesis and lymphangiogenesis in tumors: insights from intravital microscopy. Cold Spring Harb Symp Quant Biol 2002 67 239-248
26. Wirzenius M, Tammela T, Uutela M et al. Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting. J Exp Med 2007 204 (6) 1431-1440
27. Nagy J A., Chang S H., Dvorak A M., Dvorak H F. Why are tumour blood vessels abnormal and why is it important to know? Br J Cancer 2009 100 (6) 865-869
28. Paku S, Paweletz N. First steps of tumor-related angiogenesis. Lab Invest 1991 65 (3) 334-346
29. Brown L F., Yeo K T., Berse B et al. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med 1992 176 (5) 1375-1379
30. Ren G, Michael L H., Entman M L., Frangogiannis N G. Morphological characteristics of the microvasculature in healing myocardial infarcts. J Histochem Cytochem 2002 50 (1) 71-79
31. Secomb T W., Konerding M A., West C A., Su M, Young A J., Mentzer S J. Microangiectasias: structural regulators of lymphocyte transmigration. Proc Natl Acad Sci U S A 2003 100 (12) 7231-7234
32. Denekamp J, Hobson B. Endothelial-cell proliferation in experimental tumours. Br J Cancer 1982 46 (5) 711-720
33. Swayne G T., Smaje L H., Bergel D H. Distensibility of single capillaries and venules in the rat and frog mesentery. Int J Microcirc Clin Exp 1989 8 (1) 25-42
34. Chang S H., Kanasaki K, Gocheva V et al. VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation. Cancer Res 2009 69 (10) 4537-4544
35. Cox J L. Cystatins and cancer. Front Biosci 2009 14 463-474
36. Dvorak A M., Kohn S, Morgan E S., Fox P, Nagy J A., Dvorak H F. The vesiculo-vacuolar organelle (VVO): a distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation. J Leukoc Biol 1996 59 (1) 100-115
37. Feng D, Nagy J A., Hipp J, Dvorak H F., Dvorak A M. Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin. J Exp Med 1996 183 (5) 1981-1986
38. Feng D, Nagy J A., Hipp J, Pyne K, Dvorak H F., Dvorak A M. Reinterpretation of endothelial cell gaps induced by vasoactive mediators in guinea-pig, mouse and rat: many are transcellular pores. J Physiol 1997 504 (Pt 3) 747-761
39. Feng D, Nagy J A., Dvorak A M., Dvorak H F. Different pathways of macromolecule extravasation from hyperpermeable tumor vessels. Microvasc Res 2000 59 (1) 24-37
40. Nagy J A., Morgan E S., Herzberg K T., Manseau E J., Dvorak A M., Dvorak H F. Pathogenesis of ascites tumor growth: angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining. Cancer Res 1995 55 (2) 376-385
41. Egginton S, Zhou A L., Brown M D., Hudlická O. Unorthodox angiogenesis in skeletal muscle. Cardiovasc Res 2001 49 (3) 634-646
42. Goffin J R., Straume O, Chappuis P O. et al. Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer. Br J Cancer 2003 89 (6) 1031-1034
43. Straume O, Chappuis P O., Salvesen H B. et al. Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers. Cancer Res 2002 62 (23) 6808-6811
44. McKee P. Pathology of the Skin with Clinical Correlations. London, United Kingdom Mosby International 1996
45. Nagy J A., Dvorak A M., Dvorak H F. VEGF-A(164/165) and PlGF: roles in angiogenesis and arteriogenesis. Trends Cardiovasc Med 2003 13 (5) 169-175
46. Fu Y, Nagy J, Dvorak A, Dvorak H. Tumor blood vessels: structure and function In: Teicher B, Ellis L Cancer Drug Discovery and Development. Antiangiogenic Agents in Cancer Therapy. Totowa, NJ Humana Press 2007 205-224
47. Baker J L. Retinal capillary hemangioma. J Am Optom Assoc 1991 62 (10) 776-779
48. Farah M E., Uno F, Höfling-Lima A L., Morales P H., Costa R A., Cardillo J A. Transretinal feeder vessel ligature in von Hippel-Lindau disease. Eur J Ophthalmol 2001 11 (4) 386-388
49. Goel A, Muzumdar D, Desai K, Chagla A. Retroorbital hemangiopericytoma and cavernous sinus schwannomacase report. Neurol Med Chir (Tokyo) 2003 43 (1) 47-50
50. Folberg R, Hendrix M J., Maniotis A J. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 2000 156 (2) 361-381
51. Hess A R., Seftor E A., Gruman L M., Kinch M S., Seftor R E., Hendrix M J. VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry. Cancer Biol Ther 2006 5 (2) 228-233
52. Lin A Y., Ai Z, Lee S C. et al. Comparing vasculogenic mimicry with endothelial cell-lined vessels: techniques for 3D reconstruction and quantitative analysis of tissue components from archival paraffin blocks. Appl Immunohistochem Mol Morphol 2007 15 (1) 113-119
53. McDonald D M., Munn L, Jain R K. Vasculogenic mimicry: how convincing, how novel, and how significant? Am J Pathol 2000 156 (2) 383-388
54. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002 29 (6, suppl 16) 10-14
55. Kim K J., Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993 362 (6423) 841-844
56. Jain R K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005 307 (5706) 58-62
57. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003 111 (9) 1287-1295
58. Xue Q, Nagy J A., Manseau E J., Phung T L., Dvorak H F., Benjamin L E. Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase. Arterioscler Thromb Vasc Biol 2009 29 (8) 1172-1178
59. Seaman S, Stevens J, Yang M Y., Logsdon D, Graff-Cherry C, St Croix B. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 2007 11 (6) 539-554
60. Shih S C., Zukauskas A, Li D et al. The L6 protein TM4SF1 is critical for endothelial cell function and tumor angiogenesis. Cancer Res 2009 69 (8) 3272-3277